Literature DB >> 32965541

Risk of falls in patients with low bone mineral density : Analysis of placebo arms from clinical trials.

Luis Möckel1.   

Abstract

BACKGROUND: Falls are a major risk factor for osteoporotic fractures. Therefore, the aim of this study was to analyze the risk of falls in patients with low bone mineral density (BMD) and osteoporosis.
METHODS: The risk of falls in patients with low BMD and/or osteoporosis was analyzed using data from placebo arms of clinical trials, indexed on clinicaltrials.gov. The risk was estimated using a single arm meta-analysis method and by applying a binary random effects model. In addition, meta-regression analyses were performed to identify associations between risk of falls and age, body mass index (BMI) and BMD.
RESULTS: A total of 8762 patients from placebo arms of clinical trials were included into the analysis. Risk of falls was 5.2% (0.052, 95% confidence interval [95% CI] 0.022-0.082; n = 8714; I2 = 97.3%, p ≤ 0.001) in patients with low BMD and/or osteoporosis and 5.9% (0.059, 95% CI 0.036-0.083; n = 7819; I2 = 87.8%, p ≤ 0.001) in patients with osteoporosis. A significant association with risk of falls was identified for age in patients with low BMD and/or osteoporosis. BMD at total hip (TH; coefficient -0.077, 95% CI: -0.113--0.040, p ≤ 0.001; n = 7715) and femoral neck (FN; coefficient -0.044, 95% CI -0.065--0.023, p ≤ 0.001; n = 7662) were significantly associated with risk of falls in patients with osteoporosis.
CONCLUSION: This analysis identified the risk of falls in patients with low BMD and osteoporosis and an association of falls with age and BMD. Therefore, patients with osteoporosis need to receive mandatory fall risk mitigation measures, and the BMD at total hip or femoral neck could function as an indicator for the risk of falling.
© 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Frailty; Meta-analysis; Osteoporosis; Predictor of falls; Risk factor for fractures

Mesh:

Year:  2020        PMID: 32965541     DOI: 10.1007/s00391-020-01784-5

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  18 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Jonathan D Adachi; Claudie Berger; Rich Barron; Derek Weycker; Tassos P Anastassiades; K Shawn Davison; David A Hanley; George Ioannidis; Stuart A Jackson; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; William D Leslie; Suzanne N Morin; Alexandra Papaioannou; Jerilynn C Prior; Erinda Shyta; Amanda Silvia; Tanveer Towheed; David Goltzman
Journal:  Arch Osteoporos       Date:  2019-05-16       Impact factor: 2.617

3.  Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.

Authors:  Kim Brixen; Roland Chapurlat; Angela M Cheung; Tony M Keaveny; Thomas Fuerst; Klaus Engelke; Robert Recker; Bernard Dardzinski; Nadia Verbruggen; Shabana Ather; Elizabeth Rosenberg; Anne E de Papp
Journal:  J Clin Endocrinol Metab       Date:  2013-01-21       Impact factor: 5.958

4.  Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults.

Authors:  R Armamento-Villareal; L Aguirre; N Napoli; K Shah; T Hilton; D R Sinacore; C Qualls; D T Villareal
Journal:  Osteoporos Int       Date:  2013-07-27       Impact factor: 4.507

5.  Associations between obesity and overweight and fall risk, health status and quality of life in older people.

Authors:  Rebecca J Mitchell; Stephen R Lord; Lara A Harvey; Jacqueline C T Close
Journal:  Aust N Z J Public Health       Date:  2014-02       Impact factor: 2.939

6.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

7.  Fracture risk and zoledronic acid therapy in men with osteoporosis.

Authors:  Steven Boonen; Jean-Yves Reginster; Jean-Marc Kaufman; Kurt Lippuner; Jose Zanchetta; Bente Langdahl; Rene Rizzoli; Stanley Lipschitz; Hans Peter Dimai; Richard Witvrouw; Erik Eriksen; Kim Brixen; Luis Russo; Frank Claessens; Philemon Papanastasiou; Oscar Antunez; Guoqin Su; Christina Bucci-Rechtweg; Josef Hruska; Elodie Incera; Dirk Vanderschueren; Eric Orwoll
Journal:  N Engl J Med       Date:  2012-11-01       Impact factor: 91.245

8.  Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data.

Authors:  M Bonafede; N Shi; R Barron; X Li; D B Crittenden; D Chandler
Journal:  Arch Osteoporos       Date:  2016-07-30       Impact factor: 2.617

9.  Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis.

Authors:  Suey S Y Yeung; Esmee M Reijnierse; Vivien K Pham; Marijke C Trappenburg; Wen Kwang Lim; Carel G M Meskers; Andrea B Maier
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-04-16       Impact factor: 12.910

10.  Osteocalcin is necessary and sufficient to maintain muscle mass in older mice.

Authors:  Paula Mera; Kathrin Laue; Jianwen Wei; Julian Meyer Berger; Gerard Karsenty
Journal:  Mol Metab       Date:  2016-07-16       Impact factor: 7.422

View more
  1 in total

Review 1.  [Fall prevention in old people through occupational therapy home assessment, consultation and modification: a process outline].

Authors:  Sara Mohr; Christian Müller; Frank Hildebrand; Markus Laubach
Journal:  Z Gerontol Geriatr       Date:  2022-09-07       Impact factor: 1.292

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.